DiaMedica Therapeutics Inc. (DMAC) PT Lowered to $14 at Lake Street Capital Markets
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
DiaMedica Therapeutics Inc. (DMAC) Reports Q4 Results, Issues Business Update
March 14, 2022 4:46 PM EDTDiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today provided a business update and released financial results for the year ended December 31, 2021. Management will host a conference call Tuesday, March 15, 2022, at 8:00AM Eastern Time / 7:00AM Central Time, to discuss its business update and full year financial results.
Our clinical, regulatory, financial and team building achievements in 2021 have laid a solid foundation for success, said Rick Pauls, CEO of DiaMedica. In 2022, our team is focused on executing on our Phase 2/3 ReMEDy2... More
